Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases

Yin, Guo Nan; Lee, Ho Won; Cho, Je‐Yoel; Suk, Kyoungho

doi:10.1016/j.brainres.2009.01.058

Cited by 112 publications

(89 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the same line, Korolainen et al [44] listed 26 proteins which have statistical significant change in AD. 1D-PAGE beside 2D-PAGE with LC-MS/MS was used by Yin et al [45] to identify a new biomarker in AD and they recognized 21 proteins that had different abundance between AD and controls. Also, 2D-PAGE is used to list other new biomarker for PD [45,46].…”

Section: Mass Spectrometry (Ms) Is Providing a Usefulmentioning

confidence: 99%

Proteomics Analysis for Therapeutic Options of Neurodegeneration: A Review

Ganash¹

2017

J Proteomics Bioinform

View full text Add to dashboard Cite

Section: Mass Spectrometry (Ms) Is Providing a Usefulmentioning

confidence: 99%

Proteomics Analysis for Therapeutic Options of Neurodegeneration: A Review

Ganash¹

2017

J Proteomics Bioinform

View full text Add to dashboard Cite

“…Proteins in this family facilitate the uptake of synaptic materials during synapse formation and remodeling. A proteomic study by Yin et al showed that the increased NPR level in the CSF of AD patients compared with normal controls is higher than that of PD patients, indicating that NPR is a possible marker for distinguishing AD from PD [78] . [79] .…”

Section: Synapse Lossmentioning

confidence: 99%

Cerebrospinal fluid biomarkers of Alzheimer’s disease

Sui

Yang

2014

Neurosci. Bull.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a fatal neurodegenerative disorder that takes about a decade to develop, making early diagnosis possible. Clinically, the diagnosis of AD is complicated, costly, and inaccurate, so it is urgent to fi nd specifi c biomarkers. Due to its multifactorial nature, a panel of biomarkers for the multiple pathologies of AD, such as cerebral amyloidogenesis, neuronal dysfunction, synapse loss, oxidative stress, and infl ammation, are most promising for accurate diagnosis. Highly sensitive and high-throughput proteomic techniques can be applied to develop a panel of novel biomarkers for AD. In this review, we discuss the metabolism and diagnostic performance of the well-established core candidate cerebrospinal fl uid (CSF) biomarkers (β-amyloid, total tau, and hyperphosphorylated tau). Meanwhile, novel promising CSF biomarkers, especially those identifi ed by proteomics, updated in the last fi ve years are also extensively discussed. Furthermore, we provide perspectives on how biomarker discovery for AD is evolving.Keywords: Alzheimer's disease; biomarker; cerebrospinal fl uid; β-amyloid; tau; proteomics ·Review· Introduction Alzheimer's disease (AD) is becoming more prevalent due to the increasing population of people aged over 65 [1] .It is estimated that it will affect 66 million by 2030 and 115 million by 2050 worldwide if no effective therapeutic strategies are found [2] . Clinically, AD is characterized by cognitive impairment, progressive disturbance of daily activities, many neuropsychiatric symptoms, and behavioral deterioration [3][4][5][6][7][8] . Pathologically, it is characterized by deposition of extracellular neuritic plaques composed of β-amyloid (Aβ) [9] and intracellular neurofibrillary tangles (NFTs) consisting of a hyperphosphorylated form of the microtubule-associated protein tau [10][11][12] . Besides, loss of neurons and synapses is also a pathological hallmark of AD [13][14][15] . The worldwide cost of dementia is huge and expected to skyrocket in the next few years. AD may become one of the most marked social, health, and economic challenges in the twenty-fi rst century [16] .Clinically, the procedure for the diagnosis of AD is diffi cult and complex. Neuropsychological tests, such as the mini-mental state examination, magnetic resonance imaging of hippocampal volume, and clinical assessment, are used to aid in diagnosis. However, a defi nitive diagnosis of AD requires confirmation at autopsy. It is estimated to take 8-10 years or longer before mild cognitive impairment (MCI) develops into AD [17,18] . Meanwhile, intervention therapies work most effectively in the early stage of AD. Thus, it is urgent and feasible to seek novel specifi c biomarkers to aid in diagnosis and the evaluation of treatments [19] . Surrounding the brain and spinal cord, cerebrospinal fluid (CSF) is an ideal source refl ecting biochemical changes in the brain of the AD patient [20] . Extensive studies have focused on seeking AD biomarkers in CSF.A comprehensive search of the Web of Science (Janua...

show abstract

“…Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS); Multiple Sclerosis (MS); Huntington's disease (HD); MachadoJoseph disease; Amyloid Polyneuropathy Family are characterized by a progressive loss of anatomically or physiologically related neuronal systems (cognitive function, dementia, and problems with movements) [1][2][3][4][5]. With extended life expectancy worldwide, patients suffering from these pathologies will increase in the coming years.…”

Section: Introductionmentioning

confidence: 99%